European Biophysics Journal

, Volume 35, Issue 5, pp 446–450 | Cite as

Targeting cancer cells: magnetic nanoparticles as drug carriers

  • Christoph Alexiou
  • Roswitha J. Schmid
  • Roland Jurgons
  • Marcus Kremer
  • Gerhard Wanner
  • Christian Bergemann
  • Ernst Huenges
  • Thomas Nawroth
  • Wolfgang Arnold
  • Fritz G. Parak
Biophysics Letter

Abstract

Magnetic drug targeting employing nanoparticles as carriers is a promising cancer treatment avoiding side effects of conventional chemotherapy. We used iron oxide nanoparticles covered by starch derivatives with phosphate groups which bound mitoxantrone as chemotherapeutikum. In this letter we show that a strong magnetic field gradient at the tumour location accumulates the nanoparticles. Electron microscope investigations show that the ferrofluids can be enriched in tumour tissue and tumour cells.

Keywords

Cell biophysics Biological tissue Microscopy 

References

  1. Alexiou C, Arnold W, Klein RJ, Parak FG, Hulin P, Bergemann C, Erhardt W, Wagenpfeil S, Lübbe AS (2000) Locoregional cancer treatment with magnetic drug targeting Cancer Res 60:6641–6648Google Scholar
  2. Alexiou C, Jurgons R, Schmid RJ, Bergemann C, Henke J, Erhardt W, Huenges E, Parak FG (2003) Magnetic drug targeting—biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment J Drug Target 11:139–149CrossRefGoogle Scholar
  3. Bergemann C (1998) Magnetische Flüssigkeiten für den Transport von diagnostisch und therapeutisch wirksamen Substanzen Deutsches Patentamt, Offenlegungsschrift DE 19624426 A1Google Scholar
  4. Langer R, (2001) Drug delivery: drugs on target Science 293:58–59CrossRefGoogle Scholar
  5. Lübbe AS, Bergemann C, Huhnt W, Fricke T, Riess H, Brock JW, Huhn D (1996a) Preclinical experiences with magnetic drug targeting: tolerance and efficacy Cancer Res 56:4694–4701Google Scholar
  6. Lübbe AS, Bergemann C, Riess H, Schriever F, Reichardt P, Possinger K, Matthias M, Dorken B, Herrmann F, Gurtler R, Hohenberger P, Haas N, Sohr R, Sander B, Lemke A-J, Ohlendorf D, Huhnt W, Huhn D (1996b) Clinical experiences with magnetic drug targeting: a phase I study with 4’-epidoxorubicin in 14 patients with advanced solid tumors Cancer Res. 56:4686–4693Google Scholar
  7. Weissleder R, Stark DD, Engelstad BL, Bacon BR, Compton CC, White DL, Jacobs P, Lewis J (1989) Superparamagnetic iron oxide: pharmacokinetics and toxicity Am J Roentgenol 152:167–173Google Scholar

Copyright information

© EBSA 2006

Authors and Affiliations

  • Christoph Alexiou
    • 1
  • Roswitha J. Schmid
    • 1
  • Roland Jurgons
    • 1
  • Marcus Kremer
    • 2
  • Gerhard Wanner
    • 3
  • Christian Bergemann
    • 4
  • Ernst Huenges
    • 5
  • Thomas Nawroth
    • 5
  • Wolfgang Arnold
    • 6
  • Fritz G. Parak
    • 5
  1. 1.Klinik und Poliklinik für Hals- Nasen- Ohren- kranke, Universität Erlangen – NürnbergErlangenGermany
  2. 2.Institut für Pathologie, Klinikum rechts der Isar, TUMMunichGermany
  3. 3.Fakultät für Biologie I der LMU LMU MunichGermany
  4. 4.chemicellBerlinGermany
  5. 5.Physik - Department E17TUMMunichGermany
  6. 6.Hals- Nasen- Ohrenklinik und Polyklinik rechts der Isar, TUMMunichGermany

Personalised recommendations